XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations
8 Articles
8 Articles
XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations
CAMBRIDGE, Mass., June 29, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced an expansion of its research collaboration with Pfizer…
REPORTING. The recent partnership between the Benchling Biotech R&D platform and the Anthropic Generative AI specialist, which aims to put Claude LLM at the service of accelerated drug discovery, illustrates the hopes raised by the Generative AI to accelerate the marketing of new treatments. If any miraculous progress is to be excluded, the AI can save researchers valuable time and allow significant savings.
Pfizer (NYSE:PFE) Expands Collaboration With XtalPi To Enhance Drug Discovery Platform
Pfizer (NYSE:PFE) experienced a 2.98% price move over the past month, coinciding with new strategic collaborations. Notably, the company's expanded research partnership with XtalPi aims to advance drug discovery technologies, which could enhance long-term innovation prospects. Additionally, its involvement in the FIBRE Consortium and positive Phase 3 study results for products like HYMPAVZI™ highlight progress in product development. These devel…
Evotec Joins Consortium to Revolutionize Kidney Injury Drug Discovery
Evotec (EVO) has recently joined the NURTuRE-AKI Consortium, a global collaboration of leading research institutions and pharmaceutical companies, in an effort to advance drug discovery for acute kidney injury (AKI). This move marks a significant step in the fight against kidney disease, which affects millions of people worldwide and has a high mortality rate. AKI is a common complication in hospitalized patients and can lead to severe kidney da…
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium